Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Status:
Not yet recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, open-label, non-comparative Phase 1/2 study on the safety and
efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with
diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type recurrent glioblastoma
(glioblastoma expansion cohort in Phase 1 and Phase 2).